Table 1 Prevalence and HIV testing rates per HIV indicator condition before and after implementation of HIV teams
Prevalence of HIV indicator conditions | HIV testing rate | |||
|---|---|---|---|---|
HIV indicator condition | Pre-implementation of HIV teams, n (%) | Post- implementation of HIV teams, n (%) | Pre-implementation of HIV teams, n (%) | Post-implementation of HIV teams, n (%) |
Sexually transmitted infection | 69 (63.9) | 485 (57.3) | 20 (29.0) | 161 (33.2) |
Herpes zoster | 16 (14.8) | 122 (14.4) | 0 (0) | 13 (10.7) |
Community acquired pneumonia | 8 (7.4) | 101 (12.0) | 1 (12.5) | 2 (2.0) |
Seborrheic dermatitis/eczema | 1 (0.9) | 35 (4.1) | 0 (0) | 9 (25.7) |
Unexplained weight loss | - | 31 (3.7) | - | 13 (41.9) |
Unexplained oral candidiasis | 5 (4.7) | 21 (2.5) | 1 (20.0) | 4 (19.0) |
Unexplained lymphadenopathy | 1 (0.9) | 21 (2.5) | 0 (0) | 8 (38.1) |
Unexplained leukocytopenia | 2 (1.9) | 7 (0.8) | 1 (50.0) | 2 (28.6) |
Unexplained chronic diarrhea | - | 7 (0.8) | - | 0 (0) |
Severe or atypical psoriasis | 1 (0.9) | 6 (0.7) | 0 (0) | 2 (33.3) |
Mononucleosis-like illness | 4 (3.7) | 6 (0.7) | 0 (0) | 1 (16.7) |
Unexplained thrombocytopenia | 1 (0.9) | 4 (0.5) | 0 (0) | 0 (0) |
Total | 108 | 846 | 23 (21.3)* | 215 (25.4)* |